• br STAR Methods br Author Contributions br Acknowledgments W

  2024-06-05

  

  STAR★Methods Author Contributions Acknowledgments We thank Craig D. Wenger and Neva C. Durand for helpful advice, guidance, and discussions. D.H.P. is supported by the NIH National Human Genome Research Institute (NHGRI) (grant R00HG008662) and the Damon Runyon Cancer Research Foundation (D

• In the early s in addition to

  2024-06-05

  

  In the early 2000s, in addition to above-mentioned plant derived compounds, several peptide fragments from protein sources (e.g. gelatin, egg yolk, meat, fish, chicken, legumes) have been also confirmed as potential natural antioxidants and extensive studies about bioactive peptides have been conduc

• Most clinically approved antiangiogenic drugs are aimed

  2024-06-05

  

  Most clinically approved antiangiogenic drugs are aimed at blocking the action of vascular endothelial growth factor, or VEGF, which is accepted to be the most important tumor-derived angiogenic factor, stimulating proliferation and migration of endothelial cells, as well as branching of vessels (Fe

• br AMPK as a druggable target

  2024-06-05

  

  AMPK as a druggable target AMPK signaling has attracted considerable attention within the past decades, owing to the capacity of pharmacological compounds (e.g., 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside [AICAR] and metformin) or natural compounds (e.g., resveratrol) to activate AMPK in

• br Conflict of interest statement

  2024-06-05

  

  Conflict of interest statement Introduction The global prevalence of Alzheimer's disease (AD) is expected to increase to 106 million in 2050 from 30 million in 2010 (Brookmeyer et al., 2007), which will further impose a significant economic burden on health systems and society as a whole (Broo

• br Materials and methods br Results br Discussion In the

  2024-06-05

  

  Materials and methods Results Discussion In the present study, we identified HBP1 as a novel substrate of AKT. This was demonstrated by in vitro phosphorylation assays and western blotting using phosphosite-specific antibodies. Three sites were identified by mass spectrometry and mutagenesi

• It has been reported that HT R involves in type

  2024-06-05

  

  It has been reported that 5-HT2R involves in type 2 diabetes mellitus and 5-HT-induced IR [22,23]. The present study also demonstrated that it is 5-HT2R rather than other 5-HT receptors, including 5-HT1BR and 5-HT7R, in the liver that mediates HFD-induced abnormality of hepatic lipid metabolism, and

• The assay performance was estimated using Z factors plotted

  2024-06-04

  

  The assay performance was estimated using Z′-factors (plotted in Fig. 2A) according to Zhang et al. calculated for each plate comparing positive (in the absence of an inhibitor) and negative controls (in the presence of an AdK inhibitor). The mean Z′-factor±SD was determined to be 0.7±0.1, indicativ

• br Acknowledgements br Introduction Resistant hypertension R

  2024-06-04

  

  Acknowledgements Introduction Resistant hypertension (RH), is defined as blood pressure (BP) > 140/90 mm Hg despite three full doses antihypertensive drugs including a diuretic. Controlled hypertensive patients taking four WIN 64338 hydrochloride receptor or more of antihypertensives are also

• Regarding the HT B receptors they act as terminal receptors

  2024-06-04

  

  Regarding the 5-HT1B receptors, they act as terminal receptors and are involved in the presynaptic regulation of the release of 5-HT. But at spinal level these receptors are principally situated post-synaptically (Sari, 2004). The ability of autoreceptors to regulate extracellular levels of 5-HT dur

• However cancer and fibrotic diseases are the most extensivel

  2024-06-04

  

  However, cancer and fibrotic diseases are the most extensively studied disease states. ATX is connected to various cancers because it can stimulate chemokinesis and chemotaxis in melanoma cells. Upregulated ATX AZD0530 has been reported in breast cancer,, prostate cancer, thyroid cancer, non-small

• Jesus et al discovered a new series of azaindole

  2024-06-04

  

  Jesus et al. discovered a new series of azaindole as Aurora inhibitors through various modification of GSK1070916 (47). They synthesized series from modification of the GSK1070916 and evaluated for in-vitro Aurora-B/INCENP and Aurora-A/TPX2 inhibition assays. Modified paf receptor 48 and 49 showed I

• Comparison of the GLUT positive plus ACLY negative group

  2024-06-04

  

  Comparison of the GLUT1-positive plus ACLY negative group with the GLUT1-negative plus ACLY positive group indicated no significant difference with respect to disease-free survival and overall survival. However, some obvious differences in histological types were found in their formation. A previous

• br ACL Inhibition Lowering Blood LDL C to Reduce

  2024-06-04

  

  ACL Inhibition: Lowering Blood LDL-C to Reduce ASCVD Risk Given its strategic position in the lipid biosynthesis pathway, ACL has been considered an attractive target for lipid-lowering even before statins and their effects on cholesterol homeostasis were elucidated (Box 2). Cells carefully maint

• br ACL Inhibition Lowering Blood LDL C to Reduce

  2024-06-04

  

  ACL Inhibition: Lowering Blood LDL-C to Reduce ASCVD Risk Given its strategic position in the lipid biosynthesis pathway, ACL has been considered an attractive target for lipid-lowering even before statins and their effects on cholesterol homeostasis were elucidated (Box 2). Cells carefully maint

15044 records 84/1003 page Previous Next First page 上5页 8182838485 下5页 Last page